ONUREG
Drug
Celgene Corporation
Total Payments
$3.0M
Transactions
7,517
Doctors
3,287
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $200,835 | 362 | 203 |
| 2023 | $408,130 | 517 | 325 |
| 2022 | $1.1M | 3,472 | 1,830 |
| 2021 | $767,140 | 2,597 | 1,448 |
| 2020 | $443,768 | 569 | 398 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.7M | 593 | 56.0% |
| Consulting Fee | $472,892 | 232 | 16.0% |
| Unspecified | $365,447 | 23 | 12.3% |
| Travel and Lodging | $212,844 | 466 | 7.2% |
| Food and Beverage | $194,321 | 6,144 | 6.6% |
| Education | $40,312 | 52 | 1.4% |
| Space rental or facility fees (teaching hospital only) | $7,950 | 3 | 0.3% |
| Compensation for serving as faculty or as a speaker for a medical education program | $5,931 | 3 | 0.2% |
| Grant | $4,000 | 1 | 0.1% |
Payments by Type
General
$2.6M
7,494 transactions
Research
$365,447
23 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| PhI CC-486 Combo w/ Venetoclax in AML (CC-486-AML-004 (Umbrella)) - A Phase 1B, Open-label, Global, Multicenter, Dose Determination Study to Evaluate Safety, Tolerability, and Preliminary Efficacy of CC-486 (ONUREG ) in Combination Therapy in Subjects wit | Celgene Corporation | $178,700 | 0 |
| PhI/II CC-486 Combo in AML (CC-486-AML-004 (Umbrella)) - A Phase 1B, Open-label, Global, Multicenter, Dose Determination Study to Evaluate Safety, Tolerability, and Preliminary Efficacy of CC-486 (ONUREG ) in Combination Therapy in Subjects with Acute Mye | Celgene Corporation | $83,300 | 0 |
| A Phase 1B, Open-label, Global, Multicenter, Dose - A Phase 1B, Open-label, Global, Multicenter, Dose Determination Study to Evaluate Safety, Tolerability, and Preliminary Efficacy of CC-486 (ONUREG ) in Combination Therapy in Subjects with Acute Myeloid | Celgene Corporation | $38,562 | 0 |
| A PHASE 1B, OPEN-LABEL, GLOBAL, MULTICENTER, DOSE DETERMINATION STUDY TO EVALUATE SAFETY, TOLERABILITY, AND PRELIMINARYEFFICACY OF CC-486 (ONUREG) IN COMBINATIONTHERAPY IN SUBJECTS WITH ACUTE MYELOID LEUKEMIA (AML) | E.R. Squibb & Sons, L.L.C. | $27,796 | 0 |
| (CC-486-MDS-006) PhII CC-486 mono and combo with Durvalumab in MDS Post HMA failures | Celgene Corporation | $17,658 | 0 |
| A Phase 2, Open-Label, Single-Arm Rollover Study t | Celgene Corporation | $8,149 | 0 |
| A Phase 2, Open-Label, Single-Arm Rollover Study t - A Phase 2, Open-Label, Single-Arm Rollover Study to Evaluate Long-Term Safety in Subjects who Participated in other Celgene Sponsored CC-486 (Oral Azacitidine) Clinical Trials in Solid Tumors and Hemato | Celgene Corporation | $6,268 | 0 |
| (CC-486-GEN-001) PhIV Open-Label Rollover Study LT Extension CC-486 in Heme | Celgene Corporation | $5,015 | 0 |
Top Doctors Receiving Payments for ONUREG
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | West Hollywood, CA | $379,029 | 46 |
| George Yaghmour | Hematology & Oncology | Los Angeles, CA | $210,739 | 123 |
| , MD, MA | Medical Oncology | Durham, NC | $209,566 | 147 |
| , M.D | Hematology | Hackensack, NJ | $151,392 | 88 |
| , MD | Hematology & Oncology | Nashville, TN | $100,246 | 76 |
| Bart Scott | Medical Oncology | Seattle, WA | $80,864 | 70 |
| , M.D | Hematology & Oncology | Cleveland, OH | $68,195 | 32 |
| , MD | Internal Medicine | Durham, NC | $61,853 | 32 |
| , MD | Medical Oncology | Orlando, FL | $59,374 | 27 |
| , M.D | Hematology & Oncology | Sioux Falls, SD | $49,965 | 44 |
| , M.D | Hematology & Oncology | Wexford, PA | $45,880 | 26 |
| , M.D | Specialist | Columbia, MD | $44,514 | 28 |
| , M.D | Hematology & Oncology | Annapolis, MD | $44,427 | 23 |
| , MD | Hematology & Oncology | Miramar, FL | $40,887 | 28 |
| , M.D | Hematology & Oncology | Maywood, IL | $40,850 | 27 |
| , MD | Internal Medicine | Stony Brook, NY | $38,699 | 24 |
| , MD00022875 | Hematology & Oncology | Eugene, OR | $37,209 | 34 |
| , M.D | Specialist | Sacramento, CA | $35,767 | 17 |
| , M.D | Hematology & Oncology | Tampa, FL | $34,717 | 4 |
| , MD | Internal Medicine | Louisville, KY | $34,620 | 36 |
| Michael Bishop | Hematology & Oncology | New Lenox, IL | $32,972 | 16 |
| , MD | Internal Medicine | New York, NY | $32,409 | 9 |
| , M.D | Specialist | Atlanta, GA | $28,379 | 21 |
| , M.D | Hematology & Oncology | Pascagoula, MS | $26,714 | 34 |
| , D.O | Hematology & Oncology | Miami, FL | $25,216 | 21 |
Ad
Manufacturing Companies
- Celgene Corporation $1.6M
- E.R. Squibb & Sons, L.L.C. $1.3M
Product Information
- Type Drug
- Total Payments $3.0M
- Total Doctors 3,287
- Transactions 7,517
About ONUREG
ONUREG is a drug associated with $3.0M in payments to 3,287 healthcare providers, recorded across 7,517 transactions in the CMS Open Payments database. The primary manufacturer is Celgene Corporation.
Payment data is available from 2020 to 2024. In 2024, $200,835 was paid across 362 transactions to 203 doctors.
The most common payment nature for ONUREG is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.7M, 56.0% of total).
ONUREG is associated with 8 research studies, including "PhI CC-486 Combo w/ Venetoclax in AML (CC-486-AML-004 (Umbrella)) - A Phase 1B, Open-label, Global, Multicenter, Dose Determination Study to Evaluate Safety, Tolerability, and Preliminary Efficacy of CC-486 (ONUREG ) in Combination Therapy in Subjects wit" ($178,700).